Clinical Trial Update: Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing cabozantinib (XL184) to mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer was…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• COMETRIQ (CABOZANTINIB)
• Novantrone (mitoxantrone)

Snippet

Sponsor: Exelixis | Conditions: Prostate Cancer, Castration Resistant Prostate Cancer | Phase 3 | Status: TERMINATED | Results posted: 2018-05-23